GenMark Diagnostics, Inc (NASDAQ:GNMK) has been given an average rating of “Buy” by the nine analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $11.00.

GNMK has been the topic of a number of research reports. BidaskClub raised shares of GenMark Diagnostics from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 1st. Canaccord Genuity boosted their price objective on shares of GenMark Diagnostics from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, June 29th. Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 18th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of GenMark Diagnostics in a research report on Tuesday, July 31st. Finally, ValuEngine raised shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 10th.

In other GenMark Diagnostics news, CEO Hany Massarany sold 6,203 shares of the company’s stock in a transaction on Friday, August 24th. The shares were sold at an average price of $7.16, for a total transaction of $44,413.48. Following the sale, the chief executive officer now directly owns 682,491 shares of the company’s stock, valued at $4,886,635.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 20,230 shares of company stock worth $147,242 over the last ninety days. Insiders own 7.50% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Thrivent Financial for Lutherans raised its position in GenMark Diagnostics by 1.3% during the first quarter. Thrivent Financial for Lutherans now owns 596,762 shares of the medical equipment provider’s stock worth $3,246,000 after acquiring an additional 7,792 shares in the last quarter. Needham Investment Management LLC raised its position in GenMark Diagnostics by 27.8% during the second quarter. Needham Investment Management LLC now owns 230,000 shares of the medical equipment provider’s stock worth $1,467,000 after acquiring an additional 50,000 shares in the last quarter. Penn Capital Management Co. Inc. raised its position in GenMark Diagnostics by 8.0% during the second quarter. Penn Capital Management Co. Inc. now owns 455,077 shares of the medical equipment provider’s stock worth $2,903,000 after acquiring an additional 33,644 shares in the last quarter. Donaldson Capital Management LLC raised its position in GenMark Diagnostics by 22.2% during the second quarter. Donaldson Capital Management LLC now owns 83,003 shares of the medical equipment provider’s stock worth $530,000 after acquiring an additional 15,075 shares in the last quarter. Finally, A.R.T. Advisors LLC raised its position in GenMark Diagnostics by 159.4% during the first quarter. A.R.T. Advisors LLC now owns 130,214 shares of the medical equipment provider’s stock worth $708,000 after acquiring an additional 80,024 shares in the last quarter. 99.47% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GNMK stock opened at $8.14 on Wednesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.80 and a current ratio of 2.04. The firm has a market capitalization of $455.50 million, a PE ratio of -6.73 and a beta of 0.90. GenMark Diagnostics has a 12 month low of $3.63 and a 12 month high of $9.95.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Monday, July 30th. The medical equipment provider reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09). The business had revenue of $14.94 million during the quarter, compared to the consensus estimate of $14.74 million. GenMark Diagnostics had a negative return on equity of 87.96% and a negative net margin of 91.58%. analysts anticipate that GenMark Diagnostics will post -0.85 earnings per share for the current fiscal year.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Read More: Stock Symbol

Analyst Recommendations for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.